Adagio Medical's vCLAS System Shows Strong Pivotal Trial Results for VT Treatment — Adagio Medical Holdings, Inc.

Event summary

Adagio Medical reported 6-month results from its FULCRUM-VT IDE clinical trial, showing 98% non-inducibility of targeted ventricular tachycardias (VT) at the end of the procedure.
The trial enrolled 209 patients with structural heart disease, including both ischemic and non-ischemic cardiomyopathy, and demonstrated an 84% freedom from ICD shock at 6 months.
Key safety metrics included a 2.4% rate of protocol-defined major adverse events and a 1.9% rate of 30-day VT-related hospital readmission.
The vCLAS Cryoablation System achieved equivalent results for ischemic and non-ischemic cardiomyopathy patients, a first for VT ablation technology.

The big picture

Adagio Medical's positive FULCRUM-VT trial results position its vCLAS system as a potential game-changer in VT ablation, addressing a significant unmet need in treating both ischemic and non-ischemic cardiomyopathy patients. The trial's success highlights the potential for an endocardial-only approach, which could simplify workflows and improve safety profiles compared to current technologies. If approved, the vCLAS system could become a foundational technology for VT treatment, expanding Adagio's market reach in the cardiac arrhythmia space.

What we're watching

Regulatory Approval: Whether the FDA will grant premarket approval for the vCLAS system based on these pivotal trial results.
Market Adoption: The pace at which Adagio can commercialize the vCLAS system in the U.S. if approved, given the unmet need in VT treatment.
Competitive Positioning: How Adagio's ULTA technology will compare against emerging pulsed field ablation (PFA) data and existing RF ablation benchmarks.